Skip to main content
Menu
  • Meet Idylla
    • Idylla Platform
    • Oncology Tests
    • Publications
  • Oncology
    • Oncology Tests
    • Oncologist
    • Pathologist
    • On-Demand Webinars
  • Oncology Research
    • Research Assays
    • IIS Information
    • On-Demand Webinars
  • Partnering
    • Content Partnering
    • Pharma Partnering
    • Partnering Contact
    • Global Commercialization
  • Press & Events
    • Press Releases
    • Events
  • About Us
    • Team
    • Our Distributors
    • Careers
    • Download Center
    • Contact
  • IFU
  • Secure area
  • Global
Open/Close
  • Search
  • Contact us
  • +32 15 632 600
  • Subscribe to news
  • Global

Our content partners

  1. Home
  2. Our content partners
Menu
  • Meet Idylla
    • Idylla Platform
    • Oncology Tests
    • Publications
  • Oncology
    • Oncology Tests
    • Oncologist
    • Pathologist
    • On-Demand Webinars
  • Oncology Research
    • Research Assays
    • IIS Information
    • On-Demand Webinars
  • Partnering
    • Content Partnering
    • Pharma Partnering
    • Partnering Contact
    • Global Commercialization
  • Press & Events
    • Press Releases
    • Events
  • About Us
    • Team
    • Our Distributors
    • Careers
    • Download Center
    • Contact

Pharma partners

Other partners

Immunexpress - Biocartis

Immunexpress

Together with Immunexpress we focus on the development and commercialization of SeptiCyte® RAPID on the Idylla™ Platform.  SeptiCyte® RAPID is a rapid host-response gene expression signature test that distinguishes sepsis from non-infectious systemic inflammation (INSI/SIRS). It provides actionable results in about one hour enabling physicians to optimize their patient management decisions.

Learn more
GeneproDx Biocartis

GeneproDX

Together with GeneproDX we focus on the development and commercialization of ThyroidPrint® for use on the Idylla™ Platform. ThyroidPrint® is a gene expression signature (GEP) test that can identify patients with indeterminate thyroid FNA (fine needle aspiration biopsy) that can safely forego thyroid surgery.

Learn more
Endpoint Health Biocartis

Endpoint Health

Together with Endpoint Health we focus on the development and commercialization of the Endpoint Health test for use on the Idylla™ Platform. The Endpoint Health test is a gene expression signature test that can direct therapeutic decisions in critically ill patients, such as sepsis patients.

Learn more
SkylineDx & Biocartis

SkylineDx

Together with SkylineDx we focus on the development and commercialization of the Merlin™ Assay. The Merlin Assay is a gene expression signature that, in combination with clinical and pathological parameters, helps identifying melanoma patients with intermediate thickness primary melanoma that can safely forego a sentinel lymph node surgery.

Learn more
APIS Partner

APIS

Together with APIS Technology Assays we focus on the development of the APIS Breast Cancer Subtyping Assay on Biocartis’ rapid and easy-to-use molecular diagnostics platform Idylla™.

 

Learn more
  • Meet Idylla
  • Oncology
  • Oncology Research
  • Partnering
  • Press & Events
  • About Us

Biocartis NV

Generaal De Wittelaan 11B

2800 Mechelen, Belgium

Phone: +32 15 632 600

[email protected]

 

Biocartis US

  • Subscribe to news
  • Contact us
  • Request demo
  • Download center
  • LinkedIn
  • Facebook
  • YouTube
  • Twitter
  • Cookie policy
  • Privacy policy
  • Terms of use
© 2025 Biocartis Created by O2 Agency